Article
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Hepatology (Baltimore, Md.) - 1 Dec 2008
Kuntzen Thomas, Timm Joerg, Berical Andrew, Lennon Niall, Berlin Aaron M, Young Sarah K, Lee Bongshin, Heckerman David, Carlson Jonathan, Reyor Laura L, Kleyman Marianna, McMahon Cory M, Birch Christopher, Schulze Zur Wiesch Julian, Ledlie Timothy, Koehrsen Michael, Kodira Chinnappa, Roberts Andrew D, Lauer Georg M, Rosen Hugo R, Bihl Florian, Cerny Andreas, Spengler Ulrich, Liu Zhimin, Kim Arthur Y, Xing Yanming, Schneidewind Arne, Madey Margaret A, Fleckenstein Jaquelyn F, Park Vicki M, Galagan James E, Nusbaum Chad, Walker Bruce D, Lake-Bakaar Gerond V, Daar Eric S, Jacobson Ira M, Gomperts Edward D, Edlin Brian R, Donfield Sharyne M, Chung Raymond T, Talal Andrew H, Marion Tony, Birren Bruce W, Henn Matthew R, Allen Todd M
Abstract excerpt
UNLABELLED: Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K protease mutation was reported as the dominant quasispecies in a treatment-naïve individual, raising concerns...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.